Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Adenocarcinoma · Stage III Colorectal Cancer AJCC v8 · Stage IV Colorectal Cancer AJCC v8 · Unresectable Colorectal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UF Health Cancer Institute - Gainesville, Gainesville, Florida, United States
Contact: Principal Investigator (Thomas J. George)Memorial Hospital East, Shiloh, Illinois, United States
Contact: Principal Investigator (Moh'd Khushman)University of Kansas Clinical Research Center, Fairway, Kansas, United States
Contact: Principal Investigator (Raed Al-Rajabi)University of Kansas Cancer Center, Kansas City, Kansas, United States
Contact: Principal Investigator (Raed Al-Rajabi)University of Kansas Hospital-Indian Creek Campus, Overland Park, Kansas, United States
Contact: Principal Investigator (Raed Al-Rajabi)University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States
Contact: Principal Investigator (Raed Al-Rajabi)Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters, Missouri, United States
Contact: Principal Investigator (Moh'd Khushman)Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States
Contact: Principal Investigator (Moh'd Khushman)Washington University School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Moh'd Khushman)Siteman Cancer Center-South County, St Louis, Missouri, United States
Contact: Principal Investigator (Moh'd Khushman)Siteman Cancer Center at Christian Hospital, St Louis, Missouri, United States
Contact: Principal Investigator (Moh'd Khushman)University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Contact: Principal Investigator (Susanna V. Ulahannan)Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Contact: Principal Investigator (Kristen K. Ciombor)
Study leads
Susanna V Ulahannan
Principal Investigator
Yale University Cancer Center LAO